The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / U.S. Doctor Group Calls for Ban on Drug Advertising to Consumers

U.S. Doctor Group Calls for Ban on Drug Advertising to Consumers

November 19, 2015 • By Susan Kelly

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—The American Medical Association on Tuesday called for a ban on advertising prescription drugs and medical devices directly to consumers, saying the ads drive patients to demand expensive treatments over less costly ones that are also effective.

You Might Also Like
  • Drug Industry on Tenterhooks as Maryland Price-Gouging Law Nears
  • U.S. FDA Moves to Prevent Pharma from “Gaming” Generic Drug System
  • Drug Industry Group Sues to Stop California Drug Price Law

The influential doctors’ group said the new policy reflects physicians’ concerns that marketing spending on a proliferation of advertising is helping to drive up drug prices. The group voted at its annual meeting in Atlanta to support a ban.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Direct-to-consumer advertising also inflates demand for new and more expensive drugs, even when those drugs may not be appropriate,” AMA Board Chair-elect Patrice Harris said in a statement.

The U.S. and New Zealand are the only two countries that allow direct-to-consumer advertising of prescription drugs.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

AMA says drugmakers’ spending on advertising has shot up 30% in the last two years to $4.5 billion. TV commercials for drugs, such as Bristol-Myers Squibb’s lung cancer medicine Opdivo and Gilead Sciences’ Hepatitis C treatment Harvoni, were among this year’s ad campaigns.

U.S. Democratic presidential candidate Hillary Clinton has proposed cracking down on direct-to-consumer advertising and other measures to stop what she called “price gouging” by pharmaceutical companies. Clinton’s plan would prevent companies from deducting what they spend on direct-to-consumer ads from their tax bills.

A series of court decisions has determined the ads cannot be banned outright because they are a form of commercial speech protected by the U.S. Constitution. The AMA did not address how the ban could be accomplished without being overturned in court.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

PhRMA, the largest U.S. trade group for the pharmaceutical industry, says the ads increase consumer awareness of available treatments for diseases, including undiagnosed conditions.

“Providing scientifically accurate information to patients so that they are better informed about their health care and treatment options is the goal of direct-to-consumer pharmaceutical advertising about prescription medicines,” PhRMA spokesman Tina Stow said in an email.

According to a U.S. Food and Drug Administration analysis this year, 52% of Americans believe direct-to-consumer ads do not have enough information about risks and 46% say the ads lack information about benefits.

Filed Under: Drug Updates, Legislation & Advocacy, Pharma Co. News, Professional Topics Tagged With: Advertising, Advocacy, American Medical Association, American Medical Association (AMA), cost, Drug promotion

You Might Also Like:
  • Drug Industry on Tenterhooks as Maryland Price-Gouging Law Nears
  • U.S. FDA Moves to Prevent Pharma from “Gaming” Generic Drug System
  • Drug Industry Group Sues to Stop California Drug Price Law
  • Prescription-Drug Monitoring Cuts Doctor-Shopping for Painkillers

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)